share_log

ImmunoPrecise Antibodies Analyst Ratings

Benzinga ·  Jul 12, 2023 06:07
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
07/12/2023 199% HC Wainwright & Co. → $9 Reiterates Buy → Buy
07/11/2023 132.56% Benchmark → $7 Reiterates Speculative Buy → Speculative Buy
03/21/2023 132.56% Benchmark $12 → $7 Maintains Speculative Buy
03/17/2023 199% HC Wainwright & Co. → $9 Reiterates → Buy
12/02/2022 199% HC Wainwright & Co. → $9 Initiates Coverage On → Buy
10/25/2021 298.67% Benchmark → $12 Initiates Coverage On → Buy

What is the target price for ImmunoPrecise Antibodies (IPA)?

The latest price target for ImmunoPrecise Antibodies (NASDAQ: IPA) was reported by HC Wainwright & Co. on July 12, 2023. The analyst firm set a price target for $9.00 expecting IPA to rise to within 12 months (a possible 199.00% upside). 5 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for ImmunoPrecise Antibodies (IPA)?

The latest analyst rating for ImmunoPrecise Antibodies (NASDAQ: IPA) was provided by HC Wainwright & Co., and ImmunoPrecise Antibodies reiterated their buy rating.

When is the next analyst rating going to be posted or updated for ImmunoPrecise Antibodies (IPA)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ImmunoPrecise Antibodies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ImmunoPrecise Antibodies was filed on July 12, 2023 so you should expect the next rating to be made available sometime around July 12, 2024.

Is the Analyst Rating ImmunoPrecise Antibodies (IPA) correct?

While ratings are subjective and will change, the latest ImmunoPrecise Antibodies (IPA) rating was a reiterated with a price target of $0.00 to $9.00. The current price ImmunoPrecise Antibodies (IPA) is trading at is $3.01, which is within the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment